Worldwide: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?
In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
Worldwide Healthcare
KL
Herbert Smith Freehills Kramer LLP
Article
Protected: China | Data Exclusivity Comes Into Effect
China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.
China Healthcare
SF
Spruson & Ferguson
See more

Food and Drugs Law

Article
Protected: China | Data Exclusivity Comes Into Effect
China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.
China Healthcare
SF
Spruson & Ferguson
See more

Life Sciences, Biotechnology & Nanotechnology

Article
2026 Sees China's Biotech Scene Continuing Its Ascent – But Could US Developments Mean Clouds On The Horizon?
In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 
Worldwide Healthcare
KL
Herbert Smith Freehills Kramer LLP
See more

Healthcare

Article
Protected: China | Data Exclusivity Comes Into Effect
China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.
China Healthcare
SF
Spruson & Ferguson
See more